|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 13.42 Billion
|
|
Market Size (2030)
|
USD 17.36 Billion
|
|
CAGR (2025-2030)
|
4.36%
|
|
Fastest Growing Segment
|
Online Pharmacies
|
|
Largest Market
|
Mid-West
|
Market Overview
The United States Asthma Treatment
Market was valued at USD 13.42 Billion in 2024 and is expected to reach USD 17.36
Billion by 2030 with a CAGR of 4.36%. The United
States Asthma Treatment Market is witnessing substantial growth due to the
rising prevalence of asthma across all age groups and increasing emphasis on
disease management and preventive care. With more than 25 million
Americans affected by asthma, healthcare providers and pharmaceutical companies
are focusing on improving treatment outcomes through innovative therapies.
The growing adoption of combination inhalers, leukotriene modifiers, and
long-acting beta agonists is significantly supporting market growth. Public and
private investments in respiratory health and the inclusion of asthma treatment
in national healthcare plans are increasing patient access to medications and
follow-up care. Expansion of prescription drug coverage through insurance
programs has made advanced therapies more affordable and accessible, boosting
treatment compliance.
Innovations in drug delivery systems and biologic
therapies are setting new trends in the asthma treatment landscape. Digital
inhalers equipped with sensors, Bluetooth connectivity, and integrated mobile
applications are improving medication adherence and enabling remote monitoring
by clinicians. The market is also seeing a shift toward personalized medicine,
with biologics such as monoclonal antibodies targeting eosinophilic asthma
gaining rapid acceptance among patients with moderate to severe asthma. Increased
R&D activities by leading players are resulting in the development of
once-daily and long-acting therapies, reducing the treatment burden on
patients. Public health campaigns and awareness initiatives are encouraging
early diagnosis, pushing patients to seek timely and effective treatment
options.
Despite robust growth potential, the market faces
several challenges that could hinder its pace. High costs associated with
advanced biologic therapies and branded inhalers remain a major concern,
especially for uninsured or underinsured populations. Regulatory hurdles and
lengthy approval timelines for new drug formulations can delay market entry and
innovation cycles. Another pressing issue is inconsistent patient adherence to
long-term asthma control medications, often leading to poorly managed symptoms
and increased hospitalization rates. Limited awareness about emerging therapies
among primary care providers and patients further contributes to suboptimal
treatment outcomes. Addressing these challenges through strategic
collaborations, pricing reforms, and enhanced patient education will be key to
sustaining market momentum in the coming years.
Key Market Drivers
Increasing
Investment in Research and Development
Pharmaceutical companies are investing
heavily in research and development to develop new and innovative asthma
treatments. Asthma is a complex disease that requires ongoing management and
treatment, and there is a need for new and improved treatments to address unmet
medical needs. The National Institutes of Health (NIH) in the United
States provides over USD 100 million in funding for asthma research each year,
supporting research into new treatments, disease mechanisms, and prevention
strategies. It can help to identify new drug targets and treatment
options for asthma. This can include the development of novel drugs, biologics,
or combination therapies that may provide more effective and targeted treatment
options for people with asthma.
Investment in R&D can help to
improve the understanding of the underlying mechanisms of asthma and identify
new biomarkers for diagnosis and monitoring. This can enable more personalized
treatment approaches, which may lead to better outcomes and reduced healthcare
costs. Investment in R&D can help to improve asthma management and
education, leading to better self-management of the disease and reduced
healthcare utilization. It can include the development of new devices and
technologies for monitoring and managing asthma symptoms, as well as education
programs for healthcare providers and patients.
Increasing
Prevalence of Asthma
The growing prevalence of asthma in the
United States is serving as a pivotal driver in the expansion of the asthma
treatment market. According to the CDC’s FastStats for 2023, 8.9 % of
adults and 6.7 % of children currently live with asthma. This translates to
approximately 22.3 million adults and 4.5 million children nationwide.
The elevated incidence of asthma imposes a substantial public health burden,
creating sustained demand for medications such as inhaled corticosteroids,
long-acting beta-agonists, leukotriene modifiers, and targeted biologics.
Environmental and lifestyle factors including
increased exposure to air pollutants, extended allergy seasons, and
urbanization are exacerbating the frequency and severity of asthma attacks. In
2023, the United States recorded 4.9 million physician office visits and
1.4 million emergency department visits for asthma management. The fatalities
attributed to asthma reached 3,624 that year, with a mortality rate of 1.1 per
100,000 population. These statistics underscore the critical need for
both preventative and acute care therapies, further propelling market growth.
Healthcare providers and policymakers
are responding to this trend through enhanced patient education, improved
access to diagnostic services, and support for adherence programs.
Pharmaceutical companies are increasing investments in R&D for novel drug
formulations and delivery mechanisms to meet evolving clinical requirements. The
high prevalence of asthma measured at 8.2 % of the total U.S. population in
2022 (approximately 26.8 million individuals) reinforces a stable and expanding
consumer base for both branded and generic treatment options.
Public health initiatives aiming to
reduce hospitalizations and improve disease management are influencing
treatment protocols across clinical settings. Enhanced reimbursement schemes
and shifting treatment guidelines now encourage long-term disease control using
biologics and combination inhalers. In sum, the rising prevalence of asthma accompanied
by escalating healthcare utilization and mortality constitutes a sustained
driver for the United States asthma treatment market, fostering opportunities
for innovation and growth in therapeutic strategies.
Advancements
in Pharmaceutical Treatments
Advancements in pharmaceutical treatments are playing
a significant role in driving the United States Asthma Treatment Market. The
evolution of new and improved medications, including biologics, inhalers, and
oral therapies, has transformed asthma management, offering patients more
effective and targeted options. The development of biologic therapies, such as
monoclonal antibodies, has revolutionized the treatment of severe asthma by
targeting specific immune pathways that drive inflammation. These therapies
have proven especially beneficial for patients with moderate to severe asthma
who do not respond well to conventional treatments. By targeting the root
causes of inflammation, biologics help reduce asthma exacerbations, improve
lung function, and ultimately enhance patients’ quality of life.
The emergence of inhaled therapies, such as
combination inhalers that combine corticosteroids and long-acting beta-agonists
(LABAs), has also contributed significantly to the market’s growth. These
combination products offer better adherence and more effective symptom control
compared to separate inhalers. By simplifying treatment regimens, combination
inhalers have become a preferred option for patients, particularly those with
moderate asthma who require ongoing maintenance therapy.
Innovations in oral medications, such as leukotriene
receptor antagonists (LTRAs), have further expanded treatment options for
patients. These medications help control asthma symptoms by inhibiting the
actions of leukotrienes, inflammatory molecules involved in the asthma
response. As new medications with improved efficacy, safety profiles, and fewer
side effects continue to emerge, the range of treatment options for asthma
patients expands, offering more personalized care. The ongoing development of
these advanced pharmaceutical treatments is expected to continue driving the
growth of the asthma treatment market, meeting the increasing demand for more
effective and convenient asthma management solutions.
Download Free Sample Report
Key Market Challenges
High
Cost of Advanced Therapies
One of the significant challenges facing the United
States Asthma Treatment Market is the high cost associated with advanced
therapies, particularly biologic treatments. These therapies, while highly
effective in managing severe asthma, come with a substantial price tag, which
can limit accessibility for many patients. Biologic drugs, such as monoclonal
antibodies, are often priced significantly higher than conventional asthma
medications, with costs ranging from several thousand to tens of thousands of
dollars per year per patient. This high cost can be a barrier for patients,
especially in low- and middle-income regions, where healthcare coverage and
insurance schemes may not fully support such treatments.
The high cost of advanced therapies also presents
challenges for healthcare systems, which must balance the need for innovative
treatments with budget constraints. This issue becomes more pronounced as the
number of asthma patients who require these expensive treatments grows,
increasing the financial burden on public and private health systems. For many
patients, the out-of-pocket expenses for biologic therapies can be
prohibitively expensive, leading to treatment delays, non-adherence, or, in
some cases, the inability to access necessary medications.
Pharmaceutical companies, while driving innovation in
asthma treatment, are often under pressure to reduce costs and make these
therapies more accessible. However, this challenge is complicated by the high
costs of research, development, and regulatory approval required for biologic
therapies. As the demand for such treatments increases, finding ways to reduce
costs without compromising the effectiveness of the therapies will be crucial
for ensuring that these advanced asthma treatments remain accessible to all
patients, regardless of their financial situation.
Side
Effects and Safety Concerns
Side effects and safety concerns are significant
challenges in the United States Asthma Treatment Market, particularly with the
increasing use of new therapies. While asthma treatments, including inhalers,
biologics, and oral medications, are essential in managing the disease, they
often come with a range of side effects that can compromise patient adherence
and quality of life.
Inhaled corticosteroids, widely used for managing
asthma, are effective but may cause adverse effects such as oral thrush,
hoarseness, and throat irritation. Long-term use of these drugs can also lead
to more severe complications like osteoporosis and growth suppression in
children. For patients on combination therapies that include corticosteroids
and long-acting beta-agonists (LABAs), there is an increased risk of
cardiovascular events, such as heart palpitations and hypertension, especially
in older populations. These concerns can deter patients from adhering to
prescribed regimens or lead to the discontinuation of effective treatments.
Biologic therapies, though revolutionary, are also not
without risks. These treatments target specific immune system pathways and can
result in serious side effects like allergic reactions, infections, and even
malignancies in some cases. The use of biologics in asthma treatment is
typically reserved for patients with severe disease, who may be at higher risk
for these adverse effects. However, the cost of biologic drugs and the
monitoring required for potential side effects raise barriers to their widespread
adoption.
The safety concerns surrounding these treatments are
further compounded by the complexity of asthma itself, as its triggers and
manifestations vary greatly among individuals. This variation makes it
challenging to predict which treatments will be most effective and safe for
each patient, complicating decision-making processes for both patients and
healthcare providers. As a result, addressing side effects and safety concerns
remains a critical issue in the asthma treatment market.
Key Market Trends
Integration
of Digital Health Technologies
The integration of digital health technologies is
becoming a prominent trend in the United States Asthma Treatment Market,
significantly transforming how asthma is managed and treated. Mobile applications,
wearable devices, and smart inhalers are revolutionizing the approach to asthma
care, enabling patients to actively participate in managing their condition.
Smart inhalers equipped with sensors are designed to track inhaler use, sending
real-time data to both patients and healthcare providers. This not only ensures
timely medication adherence but also offers insights into potential triggers
and symptom patterns, enhancing treatment outcomes.
Mobile applications specifically developed for asthma
management enable patients to log their symptoms, monitor medication usage, and
track environmental factors that might trigger asthma attacks. These apps
empower users to make informed decisions about their treatment and avoid
potential triggers. Through regular updates, patients can share detailed
information about their condition, which can be reviewed by healthcare
providers, fostering a collaborative approach to care. This real-time
monitoring also facilitates the timely adjustment of treatment plans, reducing
hospital visits and preventing asthma exacerbations.
The use of telemedicine is another vital aspect of
digital health integration. Virtual consultations with healthcare professionals
allow patients to access expert advice without the need for frequent in-person
visits. This is particularly beneficial for patients living in remote or
underserved areas. The combination of digital tools and telemedicine increases
accessibility to asthma care, improves medication adherence, and helps prevent
complications. These technologies collectively contribute to better asthma
control, enhanced patient engagement, and more efficient healthcare delivery,
positioning digital health solutions as a crucial component of the future of
asthma treatment.
Personalized
Medicine and Genetic Insights
Personalized medicine and genetic insights are rapidly
shaping the future of the United States Asthma Treatment Market by offering
more precise, tailored approaches to managing the condition. Advances in
genomics and molecular biology have enabled the identification of specific
genetic factors that contribute to asthma susceptibility, severity, and
response to treatment. This level of understanding allows healthcare providers
to customize treatments based on an individual’s unique genetic makeup,
ensuring more effective management of asthma with fewer side effects.
A key driver of this trend is the increasing
recognition that asthma is not a one-size-fits-all disease. It encompasses
various subtypes, each with its own underlying molecular mechanisms. Genetic
profiling, along with biomarkers, enables the classification of asthma into
specific phenotypes, such as eosinophilic asthma, which often requires
different treatment protocols compared to other types. For instance, biologic
therapies like monoclonal antibodies (e.g., Dupixent and Fasenra) are
particularly effective for patients with eosinophilic asthma, as these
therapies target the specific pathways involved in inflammation.
The growing focus on personalized medicine also
extends to the development of pharmacogenomics, where drug efficacy is
optimized based on the genetic makeup of patients. This approach helps
determine the most appropriate treatment and dosage for each individual,
minimizing the trial-and-error process that has traditionally been part of
asthma management. Genetic insights also aid in early diagnosis, allowing
healthcare providers to intervene earlier in a patient’s asthma progression,
potentially preventing more severe symptoms and complications.
As genetic testing becomes more accessible and
affordable, personalized treatments are expected to become more widespread.
This trend is anticipated to drive the demand for tailored asthma therapies,
contributing to improved patient outcomes and a shift away from generalized
treatment approaches.
Segmental Insights
Drug
Class Insights
Based
on the Drug Class, Combination Drugs emerged as the dominant segment in
the United States Asthma Treatment Market in 2024. This is due to
their enhanced ability to manage multiple symptoms of asthma with a single
formulation. Combination drugs, typically containing an inhaled corticosteroid
(ICS) and a long-acting beta-agonist (LABA), offer both anti-inflammatory and
bronchodilatory effects, making them highly effective in controlling moderate
to severe asthma cases. Their convenience in dosing and improved patient
compliance compared to using separate medications contributed significantly to
their widespread adoption among healthcare providers and patients. Healthcare
professionals increasingly prefer combination therapies as they simplify
treatment regimens and reduce the risk of patient non-adherence, which is
crucial for achieving better long-term asthma control.
Mode
of Administration Insights
Based on the Mode of Administration, Inhalers
emerged
as the dominant segment in the
United States Asthma Treatment Market in 2024. This dominance is driven by
their efficiency, convenience, and ability to deliver medication directly to
the lungs. Inhalers provide rapid symptom relief and are highly preferred for
both maintenance therapy and emergency use in asthma management. Their portable
design allows patients to carry them easily and use them whenever symptoms
arise, significantly enhancing treatment adherence and improving quality of
life for individuals with asthma. The wide variety of inhalers available,
including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and soft
mist inhalers (SMIs), has enabled healthcare providers to tailor treatment
options to individual patient needs. Technological advancements, such as smart
inhalers equipped with sensors to monitor medication usage and ensure
adherence, have further strengthened the appeal of this mode of administration.
Download Free Sample Report
Regional Insights
The Mid-West region
emerged as the dominant region in the United States Asthma
Treatment Market in 2024. This is due to a combination
of high asthma prevalence, robust healthcare infrastructure, and strong focus
on chronic disease management. States within the Mid-West, such as Illinois,
Ohio, and Michigan, have reported a significant burden of asthma across both
pediatric and adult populations, prompting increased demand for effective
treatment options. The region benefits from a well-established network of
hospitals, specialty clinics, and community health centers that actively
diagnose, manage, and treat asthma through a combination of pharmacological
therapies and patient education programs. Public health agencies
in the Mid-West have been proactive in implementing asthma control programs
that promote the use of controller medications, inhalers, and biologics, while
also addressing environmental triggers through local air quality initiatives.
Recent Developments
- In February 2025, Enveda, a
biotechnology company leveraging AI for drug discovery, announced the testing
of its lead asset, ENV-294, for a second indication: asthma. Originally
developed for atopic dermatitis, ENV-294 offers a novel approach to treating
respiratory inflammatory conditions. To support this initiative, Enveda has
established an advisory board of leading asthma research and treatment experts.
- In January 2025, Kinaset Therapeutics
announced that the U.S. Food and Drug Administration (FDA) has cleared its
investigational new drug (IND) application for frevecitinib (KN-002), an
inhaled dry powder treatment for asthma patients inadequately controlled by
standard inhaled therapies. The company plans to initiate a Phase 2b
dose-ranging trial by mid-2025.
- In October 2024, AstraZeneca announced
positive results from the Phase IIIb BATURA trial for its product, AIRSUPRA
(albuterol/budesonide). The trial demonstrated that AIRSUPRA significantly
reduced the risk of severe asthma exacerbations when used as an as-needed
rescue medication compared to albuterol alone. The study included patients with
intermittent or mild persistent asthma, including those on short-acting
beta2-agonists (SABA), low-dose inhaled corticosteroids (ICS), or leukotriene
receptor antagonists (LTRA) as maintenance therapy.
- In April 2024, AstraZeneca’s FASENRA (benralizumab)
received US FDA approval as an add-on maintenance treatment for children aged 6
to 11 with severe eosinophilic asthma. Previously approved in 2017 for patients
aged 12 and older, this new indication is backed by the Phase III TATE study, which
confirmed consistent pharmacokinetics, pharmacodynamics, safety, and
tolerability in younger patients. The recommended dosage is 30 mg for those
weighing 35 kg or more, and a newly introduced 10 mg dose for children under 35
kg. FASENRA is administered via subcutaneous injection every 4 weeks for the
first three doses, then every 8 weeks.
- In January 2024, AstraZeneca announced that AIRSUPRA
(albuterol/budesonide) is now commercially available in the U.S. by
prescription. Approved by the FDA in January 2023, AIRSUPRA is indicated for
the as-needed treatment or prevention of asthma symptoms and to prevent sudden
severe asthma attacks in adults aged 18 and older. AIRSUPRA combines a
short-acting beta2-agonist (SABA) to relax airway smooth muscles and an inhaled
corticosteroid (ICS) to reduce lung inflammation.
Key Market Players
- GlaxoSmithKline,
Plc
- AstraZeneca
Plc
- Teva
Pharmaceutical Industries Ltd.
- Merck
& Co. Inc.
- Novartis
AG
- Sanofi
SA
- Regeneron
Pharmaceutical Inc.
- F.
Hoffmann-La Roche Ltd.
- Pfizer
Inc.
- Amgen
Inc.
|
By Drug Class
|
By Mode of Administration
|
By Distribution Channel
|
By Region
|
- Short-Acting Beta-Agonists (SABA)
- Long-Acting Beta-Agonists (LABA)
- Inhaled Corticosteroids (ICS)
- Leukotriene Modifiers
- Immunomodulators
- Combination Drugs
- Others
|
- Inhalers
- Nebulizers
- Oral Medications
|
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
|
- North-East
- Mid-West
- West
- South
|
Report Scope:
In this report, the United
States Asthma Treatment Market has been segmented into the following
categories, in addition to the industry trends which have also been detailed
below:
- United
States Asthma Treatment Market, By Drug Class:
o
Short-Acting
Beta-Agonists (SABA)
o
Long-Acting
Beta-Agonists (LABA)
o
Inhaled
Corticosteroids (ICS)
o
Leukotriene
Modifiers
o
Immunomodulators
o
Combination
Drugs
o
Others
- United
States Asthma Treatment Market, By Mode of Administration:
o
Inhalers
o
Nebulizers
o
Oral
Medications
- United
States Asthma Treatment Market, By Distribution Channel:
o
Hospital
Pharmacies
o
Retail
Pharmacies
o
Online
Pharmacies
o
Others
- United
States Asthma Treatment Market, By Region:
o
North-East
o
Mid-West
o
West
o South
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in the United States Asthma Treatment
Market.
Available Customizations:
United States Asthma Treatment Market report with the given market data,
TechSci Research offers customizations according to a company's specific needs.
The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to
five).
United States Asthma Treatment Market is an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at [email protected]